Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom Clinical Practice Research Datalink
Authors' conclusion
Risk of ONJ increased after 2-3 years of treatment with antiresorptives; however, the absolute risk was low and returned to baseline shortly after treatment discontinuation.
Study context
- Population
- Cancer-free female patients aged 40–89 with, or at risk for, osteoporosis in UK Clinical Practice Research Datalink (CPRD) Aurum, followed from first osteoporosis treatment208 osteonecrosis of the jaw (ONJ) cases
- Participants
- 467,654 patients
- Comparison
- Current antiresorptive treatment by duration vs past use of antiresorptives
- Outcome
- ONJ (osteonecrosis of the jaw)
Main finding
As reported in the abstract
ONJ
Each group vs past useOdds ratio (95% CI)
2-3 years of treatment
3.0(1.5–5.7)
10 years of treatment
8.1(4.4–15)
Observational data: associations, not effects.
Further findings
ONJ incidence rate, current antiresorptive treatment (primarily alendronate)
- Incidence rates (IR) per 10,000 person-years
- 1.2 (95% CI 1.0-1.4)
Absolute risk of ONJ
- After 5 years
- ≈0.05%
- After 10 years
- ≈0.18%
- Elevated risks diminished to near zero within 6 to 9 months of discontinuation
Original publication
Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom Clinical Practice Research Datalink. Osteoporos Int. Published 14 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →